News Sentiment

NXTC sentiment intelligence

NextCure  Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.97 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Deals and strategy

74/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+4.8% over one week, -5.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Deals and strategy 74/100 classification
One-week reaction 4.8% Price confirming higher
Trend fit Trend inactive -5.1% over four weeks
Fair value -84.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 33
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
TradingView 10
Market source 6
simplywall.st 3
StocksToTrade 2
PR Newswire 2
The Business Journals 1
TipRanks 1

Event Lens

What the news is about

Classified themes
Deals and strategy 19
Market update 18
Earnings 13
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-52 of 52
TradingView Direct company coverage

NextCure, Inc. Actuals & Estimates (NASDAQ:NXTC)

NextCure, Inc. (NXTC) stock is currently priced at $1.65, having experienced significant declines over the past week, month, and year. Analysts provide a wide forecast range for NXTC, with a maximum estimate of $25.00 and a minimum of $15.00. The company's next earnings report is

Tone
Negative 29/100
Event
Earnings
Published
27 Jun 2026 03:08
Source
TradingView
TradingView Direct company coverage

NextCure, Inc. Actuals & Estimates (FWB:2US0)

This article provides financial actuals and estimates for NextCure, Inc. (FWB:2US0), including analyst price targets, historical stock performance, and upcoming earnings reports. It details the company's past earnings and revenue, current net income, employee count, and confirms

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 21:40
Source
TradingView
TradingView Direct company coverage

NXTC Forecast — Price Target — Prediction for 2027

NextCure, Inc. (NXTC) has a current stock price of $1.65, with analysts providing a wide forecast range for its future price, from a minimum of $15.00 to a maximum of $25.00. The stock has experienced significant declines recently, falling 25.23% in the past week and 77.28% in th

Tone
Negative 39/100
Event
Guidance
Published
26 Jun 2026 14:40
Source
TradingView
TradingKey Direct company coverage

NextCure Inc (NXTC) Valuation: PE, PB & Fair Value Analysis

NextCure Inc (NXTC) has a current valuation score of 7.28, placing it 242 out of 387 in the Biotechnology & Medical Research industry, with its score decreasing by 1.6 from the previous 8.88. The company's current P/E ratio is -0.10, which is significantly below its recent high b

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 10:39
Source
TradingKey
TradingView Direct company coverage

NextCure, Inc. Actuals & Estimates (BOATS:NXTC)

This article provides an overview of NextCure, Inc. (NXTC) financials, including actuals and estimates, price targets, and historical performance. It details the company's past earnings, revenue, net income, and upcoming earnings report date. Additionally, it addresses common inv

Tone
Negative 40/100
Event
Earnings
Published
26 Jun 2026 09:39
Source
TradingView
Stock Titan Direct company coverage

NextCure (NXTC) director awarded options for 2,340 shares at $2.02

NextCure, Inc. director Elaine V. Jones was granted options to acquire 2,340 shares of common stock at an exercise price of $2.02 per share, expiring on June 17, 2036. This grant vests in full on the earlier of June 18, 2027, or the date of the company's 2027 annual meeting of st

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 14:08
Source
Stock Titan
Stock Titan Direct company coverage

NextCure (NXTC) director receives 2,340 options at $2.02 strike

NextCure, Inc. director Anne Elizabeth Borgman was granted 2,340 stock options at an exercise price of $2.02 per share. These options will vest in full on the earlier of June 18, 2027, or the 2027 Annual Meeting of Stockholders, and are set to expire on June 17, 2036. Following t

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

NextCure (NXTC) director awarded 2,340 options at $2.02 exercise price

NextCure, Inc. (NXTC) director Stephen W. Webster was granted 2,340 stock options with an exercise price of $2.02 per share, expiring on June 17, 2036. The options will vest in full on the earlier of June 18, 2027, or the company's 2027 Annual Meeting of Stockholders. This grant

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Director at NextCure (NASDAQ: NXTC) granted 2,340 stock options

NextCure, Inc. director Ellen Feigal was granted 2,340 stock options with an exercise price of $2.02 per share, expiring on June 17, 2036. These options vest fully on the earlier of June 18, 2027, or the date of NextCure’s 2027 Annual Meeting of Stockholders. This transaction is

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:10
Source
Stock Titan